Company Profile

ABBOTT INDIA LTD.

NSE : ABBOTINDIABSE : 500488ISIN CODE : INE358A01014Industry : Pharmaceuticals & DrugsHouse : Abbott India - MNC
BSE16114.80-78.75 (-0.49 % )
PREV CLOSE (Rs.) 16193.55
OPEN PRICE (Rs.) 16166.90
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 868
TODAY'S LOW / HIGH (Rs.)16042.20 16300.00
52 WK LOW / HIGH (Rs.)13970.1 18450
NSE16158.40 -46.6 (-0.29 % )
PREV CLOSE(Rs.) 16205.00
OPEN PRICE (Rs.) 16202.00
BID PRICE (QTY) 16158.40 (1 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 15023
TODAY'S LOW / HIGH(Rs.) 16051.05 16299.00
52 WK LOW / HIGH (Rs.)13959.8 18679.75

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 1.54
TTM EPS (Rs.) 305.51
P/E Ratio 53.09
Book Value (Rs.) 1064.69
Face Value (Rs.) 10
MCap (Rs. in Mn) 344663.68
Price/Earning (TTM) 48.75
Price/Sales (TTM) 8.25
Price/Book (MRQ) 15.23
PAT Margin (%) 14.49
ROCE (%) 36.54
Incorporation Year : 1944

Management Info :

Munir Shaikh - Chairman Anil Joseph - Managing Director

Registered Office :

Address : Unit No. 3,Corporate Park,Sion Trombay Road,
Mumbai,
Maharashtra-400071

Phone : 022-50461000/2000/1119/1117/1116/6797 8888

Website : www.abbott.co.in

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
10May05-10-2021$ Board Meeting Intimation for Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2021 And To Recommend Dividend. Board Meeting Intimation fo
ABBOTT INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2021 ,inter alia, to consider and approve 1. The text of Audited Financial Results of the Company for the quarter and year ended March 31, 2021, along with the Audit Report of the Statutory Auditors thereon as required under Regulation 33 of the said Regulations. 2. To consider and approve the Audited Financial Statements for the year ended March 31, 2021. 3. To recommend dividend. Further please note that in terms of Abbott India Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders and in accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) (Amendment) Regulations, 2019, the Trading Window of the Company remains closed from Wednesday, March 31, 2021 to Thursday, May 20, 2021 (both days inclusive). Kindly acknowledge the receipt of the same.
ABBOTT INDIA LTD.has informed BSE that the meeting of the Board..
10May05-10-2021$Abbott India informs about board meeting Abbott India informs about b

In terms of Regulation 29(1)(a) and (e) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Abbott India has informed that a Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, May 18, 2021 for the following: To consider and approve the text of Audited Financial Results of the Company for the quarter and year ended March 31, 2021, along with the Audit Report of the Statutory Auditors thereon as required under Regulation 33 of the said Regulations, to consider and approve the Audited Financial Statements for the year ended March 31, 2021 and to recommend dividend. Further, in terms of the company’s code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders and in accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) (Amendment) Regulations, 2019, the Trading Window of the Company remains closed from Wednesday, March 31, 2021 to Thursday, May 20, 2021.

The above information is a part of company’s filings submitted to BSE.

In terms of Regulation 29(1)(a) and (e) of the Securities and E..
10May05-10-2021$Abbott India informs about newspaper publication Abbott India informs about n

Abbott India has informed that it has enclosed the copies of Public Notice published as per Regulation 47(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, in 'Business Standard (All Edition) and Loksatta' on Monday, May 10, 2021, in connection with the Meeting of the Board of Directors to be held on Tuesday, May 18, 2021.

The above information is a part of company’s filings submitted to BSE.

Abbott India has informed that it has enclosed the copies of Pu..
09Apr04-09-2021$Abbott India informs about non-applicability of large corporate entity Abbott India informs about n

With reference to the SEBI Circular-SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 with respect to Fund raising by issuance of Debt securities by Large Entities, Abbott India has confirmed that its Company is not a Large Corporate as on March 31, 2021 as per the framework provided in the aforesaid Circular.

The above information is a part of company’s filings submitted to BSE.

With reference to the SEBI Circular-SEBI/HO/DDHS/CIR/P/2018/144..
09Feb02-09-2021$ Re-Appointment Of Ms. Anisha Motwani (DIN Re-Appointment Of Ms. Anish
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Board of Directors at its Meeting held today i.e. February 9, 2021 have approved the re-appointment of Ms. Anisha Motwani (DIN: 06943493) as an Independent Director for a further term of 5 (five) years with effect from April 25, 2021, subject to approval of the Shareholders of the Company at the ensuing Annual General Meeting. Additional details required under the Listing Regulations read with SEBI Circular Nos. CIR/CFD/CMD/412015 dated September 9, 2015 and List/Comp/14/2018-19 dated June 20, 2018, are enclosed as Annexure A. We request you to kindly take the same on records.
Pursuant to Regulation 30 of the Securities and Exchange Board..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit1771.45929.3
Gross Profit 2378.8 8026.9
Operating Profit 2568.38708.3
Net Sales 10953.740931.4
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
NGL Fine-Chem (BSE)
 1679.60 (4.62%)
M.Cap ( in Cr)
1037.66
Ajanta Pharma (BSE)
 2002.95 (3.11%)
M.Cap ( in Cr)
17398.94
Solara Active Pharma (BSE)
 1742.70 (2.80%)
M.Cap ( in Cr)
6280.52
Themis Medicare (BSE)
 465.55 (5.54%)
M.Cap ( in Cr)
440.91
Cadila Healthcare (BSE)
 646.95 (2.74%)
M.Cap ( in Cr)
66231.03
Shareholding Pattern More
PROMOTERS 74.99 %
MUTUAL FUNDS/UTI 3.22 %
NON-INSTITUTION 18.47 %
FI/BANKS/INSURANCE 1.39 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes